NWL
48
4
KLAC
45
3
HRB
40
3
GM
55
6
WU
26
2
DFS
64
4
PCG
59
9
ORLY
48
3
SPG
45
2
HP
44
14
CCL
68
6
CCI
30
2
PFG
27
7
LRCX
56
4
PX
56
3
OMC
37
2
PEP
33
4
ABBV
40
5
LOW
42
14
FMC
23
7
NWL
48
4
KLAC
45
3
HRB
40
3
GM
55
6
WU
26
2
DFS
64
4
PCG
59
9
ORLY
48
3
SPG
45
2
HP
44
14
CCL
68
6
CCI
30
2
PFG
27
7
LRCX
56
4
PX
56
3
OMC
37
2
PEP
33
4
ABBV
40
5
LOW
42
14
FMC
23
7
Financhill
Back

NovaBay Pharmaceuticals 10K Form

Sell
19

NBY
NovaBay Pharmaceuticals

Last Price:
$0.53
Seasonality Move:
-0.66%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NBY News And Ratings

See the #1 stock for the next 7 days that we like better than NBY

NBY Financial Statistics

Sales & Book Value

Annual Sales: $14.7M
Cash Flow: $-2.1M
Price / Cash Flow: 0
Annual Sales: $0.22
Price / Book: 2.43

Profitability

EPS (TTM): -35.79620
Net Income (TTM): $-10.1M
Gross Margin: $7.9M
Return on Equity: -461.38%
Return on Assets: -144.37%

NovaBay Pharmaceuticals Earnings Forecast

Key NovaBay Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 21 years for NBY is 53.61%.
  • The Selling, General & Administrative Expenses for NBY have been equal to 87.12% of Gross Profit Margin.
  • The Research & Development expenses have been 0.46% of Revenue.
  • The Net Earning history of NBY is -65.46% of Total Revenues.
  • Per Share Earnings over the last 21 years have been positive in 11 years.

NovaBay Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: NBY
CUSIP: 66987P
Website: novabay.com

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 1.15
Quick Ratio: 0.75

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NBY Technical Analysis vs Fundamental Analysis

Sell
19
NovaBay Pharmaceuticals (NBY) is a Sell

Is NovaBay Pharmaceuticals a Buy or a Sell?